Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40,197 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent.
Subramanian R, Tang J, Zheng J, Lu B, Wang K, Yant SR, Stepan GJ, Mulato A, Yu H, Schroeder S, Shaik N, Singh R, Wolckenhauer S, Chester A, Tse WC, Chiu A, Rhee M, Cihlar T, Rowe W, Smith BJ. Subramanian R, et al. Among authors: wang k. Mol Pharm. 2023 Dec 4;20(12):6213-6225. doi: 10.1021/acs.molpharmaceut.3c00626. Epub 2023 Nov 2. Mol Pharm. 2023. PMID: 37917742 Free PMC article.
In vitro characterization of GS-8374, a novel phosphonate-containing inhibitor of HIV-1 protease with a favorable resistance profile.
Callebaut C, Stray K, Tsai L, Williams M, Yang ZY, Cannizzaro C, Leavitt SA, Liu X, Wang K, Murray BP, Mulato A, Hatada M, Priskich T, Parkin N, Swaminathan S, Lee W, He GX, Xu L, Cihlar T. Callebaut C, et al. Among authors: wang k. Antimicrob Agents Chemother. 2011 Apr;55(4):1366-76. doi: 10.1128/AAC.01183-10. Epub 2011 Jan 18. Antimicrob Agents Chemother. 2011. PMID: 21245449 Free PMC article.
Long-acting capsid inhibitor protects macaques from repeat SHIV challenges.
Vidal SJ, Bekerman E, Hansen D, Lu B, Wang K, Mwangi J, Rowe W, Campigotto F, Zheng J, Kato D, Chandrashekar A, Barrett J, Patel S, Wan H, Anioke T, Mercado NB, Nkolola JP, Ferguson MJ, Rinaldi WJ, Callebaut C, Blair W, Cihlar T, Geleziunas R, Yant SR, Barouch DH. Vidal SJ, et al. Among authors: wang k. Nature. 2022 Jan;601(7894):612-616. doi: 10.1038/s41586-021-04279-4. Epub 2021 Dec 7. Nature. 2022. PMID: 34875675 Free PMC article.
Human pharmacokinetics prediction with an in vitro-in vivo correction factor approach and in vitro drug-drug interaction profile of bictegravir, a potent integrase-strand transfer inhibitor component in approved biktarvy® for the treatment of HIV-1 infection.
Subramanian R, Wang J, Murray B, Custodio J, Hao J, Lazerwith S, MacLennan Staiger K, Mwangi J, Sun H, Tang J, Wang K, Rhodes G, Wijaya S, Zhang H, Smith BJ. Subramanian R, et al. Among authors: wang k, wang j. Xenobiotica. 2022 Dec;52(12):1020-1030. doi: 10.1080/00498254.2023.2169207. Epub 2023 Jan 26. Xenobiotica. 2022. PMID: 36701274
Long-acting lenacapavir protects macaques against intravenous challenge with simian-tropic HIV.
Swanstrom AE, Gorelick RJ, Welker JL, Schmidt F, Lu B, Wang K, Rowe W, Breed MW, Killoran KE, Kramer JA, Donohue D, Roser JD, Bieniasz PD, Hatziioannou T, Pyle C, Thomas JA, Trubey CM, Zheng J, Blair W, Yant SR, Lifson JD, Del Prete GQ. Swanstrom AE, et al. Among authors: wang k. EBioMedicine. 2023 Sep;95:104764. doi: 10.1016/j.ebiom.2023.104764. Epub 2023 Aug 23. EBioMedicine. 2023. PMID: 37625266 Free PMC article.
Lenacapavir Exhibits Atropisomerism-Mechanistic Pharmacokinetics and Disposition Studies of Lenacapavir Reveal Intestinal Excretion as a Major Clearance Pathway.
Zheng J, Lu B, Carr G, Mwangi J, Wang K, Hao J, Staiger KM, Kozon N, Murray BP, Bashir M, Gohdes MA, Tse WC, Schroeder S, Graupe M, Link JO, Yoon J, Chiu A, Rowe W, Smith BJ, Subramanian R. Zheng J, et al. Among authors: wang k. J Pharmacol Exp Ther. 2024 Sep 18;391(1):91-103. doi: 10.1124/jpet.124.002302. J Pharmacol Exp Ther. 2024. PMID: 39117460
Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection.
Link JO, Taylor JG, Xu L, Mitchell M, Guo H, Liu H, Kato D, Kirschberg T, Sun J, Squires N, Parrish J, Kellar T, Yang ZY, Yang C, Matles M, Wang Y, Wang K, Cheng G, Tian Y, Mogalian E, Mondou E, Cornpropst M, Perry J, Desai MC. Link JO, et al. Among authors: wang k, wang y. J Med Chem. 2014 Mar 13;57(5):2033-46. doi: 10.1021/jm401499g. Epub 2014 Jan 10. J Med Chem. 2014. PMID: 24320933 Clinical Trial.
40,197 results
You have reached the last available page of results. Please see the User Guide for more information.